Delivery of foreign genes to the digestive tract mucosa by oral administration of nonreplicating gene transfer vectors would be a very useful method for vaccination and gene therapy. However, there have been few reports on suitable vectors. In the present study, we found that plasmid DNA can be packaged in vitro into a virus-like particle (VLP) composed of open reading frame 2 of hepatitis E virus, which is an orally transmissible virus, and that these VLPs can deliver this foreign DNA to the intestinal mucosa in vivo. The delivery of plasmid DNA to the mucosa of the small intestine was confirmed by the results of immunohistochemical analyses using an expression plasmid encoding human immunodeficiency virus env (HIV env) gp120. After oral administration of VLPs loaded with HIV env cDNA, significant levels of specific IgG and IgA to HIV env in fecal extracts and sera were found. Moreover, mice used in this study exhibited cytotoxic T-lymphocyte responses specific to HIV env in the spleen, Payer's patches and mesenteric lymph nodes. These findings suggest that VLPs derived from orally transmissible viruses can be used as vectors for delivery of genes to mucosal tissue by oral administration for the purpose of DNA vaccination and gene therapy.
Introduction
The successful outcome of novel gene therapies and DNA vaccinations largely depends on the development of effective delivery systems. 1 In human applications, both the efficacy and safety of any delivery system used for gene transfer are major concerns. It has been shown that tissue-specific gene transfer by a viral vector could be achieved naturally and effectively through cell specificity of the virus receptors. 2 However, there is a risk of vector toxicity through viral infection of the host cells. Also, the limited sizes of transgenes often present a serious obstacle. Nonviral vectors, such as liposomes, are safer but do not have a cell-specific targeting component and have limited transduction both in vitro and in vivo. This limitation has been partly overcome by the development of molecular conjugates consisting of cellspecific ligands that confer cell specificity to nonviral vectors. 3, 4 The development of a system for delivering genes to or conferring immunity to mucosal tissue by oral administration would provide a convenient means for effective treatment or prevention of various human diseases, including cancers, infectious diseases and immunological disorders. 5 Since many pathogenic viruses and bacteria establish their initial infections through the mucosal surface, vaccine strategies that can stimulate mucosal immunity have been widely studied (reviewed in Ogra et al 6 ). However, there are several difficulties in oral immunization with nonreplicating molecules, such as low pH in the stomach, the presence of proteolytic enzymes in the digestive tract and the presence of physical as well as biochemical barriers associated with the mucosal surface itself. 6 Among the various nonreplicating molecules, a viruslike particle (VLP), an empty particle with a structure similar to that of an authentic virus particle, offers the possibility of a new approach for vaccine development. 7 It is expected that the VLP structure will provide resistance to severe environments in the digestive tracts and enable specific binding to the mucosal surface if an appropriate VLP is chosen. 8 However, VLPs can induce immune responses to themselves, and this is a problem for using VLPs as a vaccine vector to carry foreign DNA. A system using polyoma virus VP1 VLPs as a carrier of DNA by intranasal administration has been reported. 9 These VLPs work as an adjuvant, since DNA vaccine can induce immune responses by intranasal administration without VLPs. Hepatitis E virus (HEV) is an unclassified calicivirus-like, positive-strand RNA virus that causes human acute hepatitis by fecal-oral transmission. HEV first infects epithelial cells of the small intestine and then reaches the liver through the portal vein. It has recently been reported that overexpression of a part of open reading frame 2 (ORF2) in a baculovirus expression system results in the assembly of this protein into a VLP. 10 We have also reported that VLPs carrying foreign epitopes elicit strong mucosal and systemic immune responses to both the VLPs and exogenous epitopes without the requirement of any kind of adjuvant when orally administered to mice.
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Since infection with human immunodeficiency virus (HIV) most likely occurs through exposure of mucosal tissue to the virus, HIV-specific immune responses at mucosal sites are critical for the initial control of infection. Therefore, a nonreplicating vaccine vector that elicits mucosal immunity by oral administration would be a powerful HIV vaccine. In the present study, we found that unrelated plasmid constructs can be encapsulated into HEV-VLPs and delivered to the intestinal mucosa by oral administration. HIV DNA vaccineloaded HEV-VLPs can elicit mucosal and systemic cellular as well as humoral immune responses by oral administration.
Results

In vitro refolding of VLPs
The HEV-VLPs produced by a recombinant baculovirus system were disassembled by the removal of calcium ions (Figure 1b) . When calcium ions were supplemented to the disrupted VLPs in the presence of plasmid DNA, the DNA was encapsulated into the refolded VLPs (Figure 1c) . No significant morphological difference due to the VLP disassembling-refolding process was observed under an electron microscope.
Density shifts of VLPs and amount of plasmid DNA after DNA encapsulation Plasmid DNA encapsulation in the refolded VLPs was confirmed by CsCl equilibrium gradient centrifugation. VLP density is greater when loaded with a DNA plasmid. A heavier density gradient peak was present only when DNA was incorporated into the VLPs ( Figure  2d ). A single lighter density peak was produced for VLPs alone (Figure 2a ), refolded VLPs ( Figure 2b ) and intact VLPs in the presence of plasmid DNA (Figure 2c ). Despite the various sizes of plasmid DNA used for encapsulation, the amounts of plasmid in VLPs were almost the same (17-19 mg per 50 mg of HEV-VLPs) (Figure 2e and f) . A solution with a high concentration of plasmid DNA showed high viscosity, and VLPs including DNA were not obtained for general use in experiments. Based on these results, we used this amount (1 mg/ml) as the optimal concentration (data not shown).
Gene transfer by HEV-VLPs
Initially, four cell lines derived from mice, rabbits, monkeys and humans were studied for their ability to Figure 3 ). In contrast, no fluorescence-positive cells were observed when the cells were incubated with plasmid DNA alone or intact VLPs in the presence of plasmid DNA (data not shown). We next tried gene transduction in vivo. Mice that had orally received a vaccine of DNA expressing HIV env gp120 of the NL432 strain (pJWNL432) that was encapsulated in VLPs were killed 2 days after immunization, and the expression of HIV env protein in the digestive tract was examined. HIV env protein was found in epithelial cells of the small intestine by immunohistochemistry (Figure 4 ), indicating that the HEV structure necessary for the entry of HEV into target cells had been preserved in refolded VLPs and that the DNA encapsulated in HEV-VLPs had been delivered to intestinal tissues.
Systemic and mucosal HIV-specific humoral immune responses in mice that had orally received a vaccine of HIV DNA encapsulated in VLPs
Mice were orally or subcutaneously immunized four times at 1-week intervals with pJWNL432 either naked or encapsulated in HEV-VLPs. The serum levels of HIV envspecific IgG antibodies in mice that had received loaded VLPs were significantly higher than those in mice that had received naked DNA (Po0.05 at 12 wpi, Figure 5a and e). Moreover, specific IgA was detected at high levels in sera of mice that had received loaded VLPs but not in sera of mice that had been immunized subcutaneously (Po0.05 at 12 wpi, Figure 5b and f). HIV env-specific IgA was only detected in fecal extracts of mice that had orally received pJWNL432-encapsulated HEV-VLPs (Figure 5d and h). No specific IgG was detected in any of the fecal samples ( Figure 5c and g). The levels of HIV env-specific IgG antibodies detected in sera from subcutaneously and orally immunized mice were the same (Figure 5a and e). HEV-specific IgA was detected in both sera and fecal extracts of mice that had been orally administered VLP but not in sera or fecal extracts of mice that had been immunized subcutaneously ( 
Discussion
A large number of pathogens gain access to the human body via mucosa such as oral, nasal or genital mucosa. The best defense against these predominantly mucosal Oral administration of DNA vaccine by using virus-like particles S Takamura et al Oral administration of DNA vaccine by using virus-like particles S Takamura et al pathogens is mucosal vaccines that are capable of inducing both systemic and mucosal immunity. Recent evidence has shown that DNA vaccination can confer protection against a number of infectious agents, including viruses and bacteria, although peripheral immunization with naked DNA is less than optimal for stimulating mucosal immunity. 12, 13 In fact, it is quite difficult to induce both mucosal and systemic immune responses by oral administration of naked DNA. This study demonstrated that an orally administered DNA vaccine encapsulated in an orally transmissible virus-derived VLP induced both mucosal and systemic immunity.
The delivery of a DNA vaccine for induction of mucosal immune responses is usually achieved by gene transfer to the upper nasopharynx-associated lymphoid tissue (NALT), upper airway, salivary glands and tonsils. 5, 14 Despite its obvious convenience, oral administration is rarely successful, since it is quite difficult to protect plasmid DNA from the environment in the digestive tract. The efficacy of orally delivered DNA vaccine to NALT is improved by encapsulating plasmid DNA in poly (lactide-coglycolide) (PLG) microparticles for protection against the gastric environment. 15, 16 The immune responses to particle-borne DNA immunizations by means such as utilization of a gene gun or PLG differ from those to DNA immunizations without particles. 13 It is thought that the microparticles are actively taken up by cells such as macrophages or M cells of PP of the small intestine and thus facilitate the presentation of antigens to local immune systems. 15, 17 This mechanism is the same as that of gene gun immunization of a DNA vaccine, that is, phagocytic cells such as macrophages or dendritic cells take up plasmid DNA delivered by a gene gun. The delivered gene is expressed only in these cells. 18 Similarly, only mucosal immunity was induced in mice by oral administration of DNA-encapsulated PLG microparticles. 15, 16 It is likely that the mechanism underlying immune recognition of Oral administration of DNA vaccine by using virus-like particles S Takamura et al HEV-VLP infection is similar to that of direct intramuscular or subcutaneous DNA immunization without the use of particles. Protein expressed by HEV-VLP-infected cells is recognized by the immune surveillance system, resulting in the elicitation of Ag-specific immune responses. We showed in this study that genes could be expressed in epithelial cells in the small intestine after delivery by HEV-VLPs (Figure 4) . It is plausible that HEV-VLPs, which are derived from an orally transmissible virus, were incorporated into HEV-permissive epithelial cells in the small intestine, because they retained structures and properties similar to those of HEV particles, producing an infection similar to that induced naturally. 19 The Ag-expressing cells might be recognized by intraepithelial lymphocytes or submucous antigen-presenting cells by the same mechanism as that in the case of general virus infection.
An HEV-VLP has several advantages as a vector of DNA. Firstly, in our experience, large amounts can be easily obtained from standard cultivation protocols compared with the amounts of other VLPs obtained. The yield of purified HEV-VLPs collected from a culture supernatant of 50-100 mg/ml is more than 100 times greater than that of other VLPs. Secondly, the outcome of gene delivery in humans can be predicted using conventional laboratory animals, since HEV naturally infects various animals as well as humans through the same infectious route and target cells. 10, 20 Thirdly, HEVVLPs are stable at room temperature. Fourthly, anti-HEV immune responses had no effect on DNA administration in the present study, and this might be related to the neutralizing antibody for preventing infection with HEV.
Neutralizing antibodies to HEV for inhibiting infection
have not yet been found. This is also the case for HCV. The mechanism by which HEV is eliminated by antibodies is thought to be antibody-dependent cellmediated cytotoxicity (ADCC). The effect of induction of immune responses to DNA vaccine in our system is not clear. Thus, HEV-VLPs are an attractive vaccine vector in developing countries because these VLP can be preserved without the requirement of any particular equipment. Finally, we have reported that an HEV-VLP can carry foreign amino-acid sequences as a part of the ORF2 protein exposed on the particle surface without any morphological or biological alteration. 10 Liposomal vectors resembling retroviral envelopes endowed with targeting molecules for gene delivery have been reported. The vicronectin receptor, a v b 3 -integrin, is commonly upregulated on malignant melanoma cells, and liposome carrying an Arg-Gly-Asp (RGD) integrinbinding motif has been used for a system to deliver DNA to these tumor cells. 21 It has also been reported that targeting DNA to M cells by intranasal administration for the induction of mucosal and systemic responses can be achieved by formulating DNA with polylysine linked to viral adhesion. 22 It may be possible to design chimeric ORF2 proteins carrying these targeting molecules to retarget HEV-VLP to particular cell types.
Oral vaccination has obvious advantages for a field trial in a large-scale public health vaccination program. 23 From a practical standpoint, oral administration is less stressful for vaccine recipients and does not require professional skill for the vaccine administration. Moreover, delivery of vaccines via the intestinal tract is considered to be inherently safer than systemic injection.
Encouraging results of phase I trials using Norwalk virus VLPs have recently been reported. 24 Trials using DNA vaccines for infectious and malignancy diseases have also been conducted. 25 The results of the present study suggest that oral administration of DNA vaccine encapsulated in oral transmissible virus VLPs, HEV-VLPs, is effective for inducing both humoral and cellular immunity locally as well as systematically. HEV-VLPs might be useful not only for vaccination but also as a vector in human gene therapy.
Materials and methods
Mice BALB/c female mice were purchased from Clea Japan (Tokyo, Japan) and were housed in the Laboratory Animal Center of Mie University School of Medicine during the experimental period.
Peptide synthesis
The peptides used in this study were the HIV env CTL epitope (HIV 308-322, RIQRGPGRAFVTIGK; P18) 26 and a control peptide (HCV nonstructural protein 5 CTL epitope MSYSWTGALVTPCAAE; P17). 27 Plasmid DNA A highly efficient mammalian expression vector, pJW4303, 28 was used for efficient expression of HIV env gp120 of the NL432 strain. 29 Various sizes of plasmid DNA were also used for the in vitro packaging experiment (3.162 kb: pUC118; 5.93 kb: pJW322; 8.63 kb: pJWSIVenv; 11.2 kb: pABWN).
Production and purification of HEV-VLPs
HEV-VLPs were produced and purified by previously described methods. 10, 11 Briefly, Tn5 cells maintained in Excel 405 serum-free medium (JRH, KS) were infected with the recombinant baculovirus expressing HEV-ORF2 at an m.o.i. of 45 and cultured for 6 days. The supernatant was harvested and the recombinant baculovirus in the supernatant was pelleted by ultracentrifugation at 10 000 g for 30 min at 41C. The VLPs in the supernatant were collected by further ultracentrifugation at 100 000 g for 2 h at 41C. Pelleted VLPs were then resuspended in 10 mM potassium-[2-(N-morpholino) ethanesulfonic acid] (MES) buffer (pH 6.2) and purified on a CsCl equilibrium density gradient. The purified HEV-VLPs were spun down and resuspended in potassium-MES buffer and kept at 41C.
DNA packaging
Plasmid DNA was encapsulated into HEV-VLPs according to a previously described procedure. 30 Purified VLPs (50 mg) were disrupted by incubation in 180 ml of a buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM EGTA and 20 mM dithiothreitol. Following 30 min of incubation at room temperature, 200 mg (20 ml) of each plasmid in 50 mM Tris-HCl buffer (pH 7.5) and 150 mM NaCl was added. The disrupted VLP preparation was refolded by incubation for 1 h with increasing concentrations of CaCl 2 up to a final concentration of 5 mM. VLPs were pelleted by ultracentrifugation and resuspended in 10 mM potassium-MES buffer (pH 6.2). At each step, the VLP structure formation was confirmed by electron Oral administration of DNA vaccine by using virus-like particles S Takamura et al microscopy after negative staining, as described previously. 11 To estimate the amounts of encapsulated plasmid DNA, refolded and purified VLPs were treated with 10 IU benzonase (SIGMA-ALDRICH, Irvin, UK) for 1 h at 201C to remove DNA on the surfaces of VLPs and disrupted with EGTA (1 mM). Absorbance of the supernatant was measured for detection of plasmid DNA contents.
Density analysis of refolded VLPs
Refolded VLPs were separated on a CsCl equilibrium density gradient and fractioned into 0.2 ml aliquots. HEV-VLPs in each fraction were detected by ELISA as previously described, 10 as well as DNA contents.
Gene transfer in mammalian cells
Four cell lines (NIH/3T3 (mouse), RK13 (rabbit), COS-7 (monkey), HepG2 (human)) were used in transfection experiments. Sterilized coverslips were placed in six-well plates, and 5 Â 10 5 cells per well were seeded in the plates. After overnight culture, cells were washed twice with a medium, and about 1 mg of VLP-encapsulated EGFP expression vector (BD Bioscience Clontech, CA, USA) diluted with 0.5 ml medium was added. After 2 h of incubation at 371C, VLPs were removed. Cells were then incubated for 48 h at 371C. At the end of the culture period, cells were removed from the culture medium and washed three times with PBS. Coverslips were then mounted onto microscope slide glasses. Fluorescence of the GFP-expressing cells was observed under a fluorescence microscope.
Immunization
Mice were orally immunized four times with 50 mg protein of HEV-VLP/DNA (pJWNL432) complex or 20 mg naked pJWNL432 DNA in 100 ml of potassium-MES buffer at 1 week intervals.
Immunohistochemical analysis
At 2 days after oral immunization, the mice were killed and tissues were collected. Cryostat sections were airdried and incubated in 0.5% HIO 4 for 10 min to quench endogenous peroxidase activity. The sections were further pretreated with chicken anti-mouse IgG antibody (Chemicon International, Inc., CA, USA) to prevent nonspecific reactions of a secondary antibody. The sections were then incubated with an HIV env-specific mAb (HIV-1 IIIB gp120 mAb (902)), which was obtained through the AIDS Research and Reference Reagent Program, 31 for 30 min at 371C. The bound antibodies were visualized with a biotinated secondary antibody, HRP-labeled avidin-biotin complex (ABC-peroxidase staining kit, Elite Vector Lab. Inc., CA, USA) and 3.3 0 -diaminobenzidine tetrachloride with 0.01% H 2 O 2 . Sections were slightly counterstained with hematoxylin. An mAb (A1/3D1, ANOGEN, Canada) against hepatitis C virus core, which is same isotype to 902, was used as a control.
ELISA
Serum and fecal samples were collected at 0 (preimmunization), 2, 4, 6 and 12 weeks after the first immunization. Feces were suspended in ice-cold PBS at 200 mg/ ml, and the centrifuge supernatant was used as fecal extract. Culture plates (96-well) were coated with purified HEV-VLPs or synthesized oligopeptides (P18) at a concentration of 10 or 100 mg/well, respectively, overnight at 41C followed by 30 min of blocking with PBS containing 0.1% FBS and 0.05% Tween 20. To determine the anti-HIV env gp120 antibody responses, CV-1 cells were seeded in 96-well plates and infected with recombinant Sendai virus expressing HIV env gp120 of NL432 strain (SeV gp120), 32 and then the plates were incubated at 371C. At 3 days after infection, plates were washed and fixed with PBS containing 10% formalin for 10 min. Test samples were added to each well and incubated at room temperature for 1 h. For detection of anti-HIV env gp120 antibody, test samples were reacted with wild-type Sendai virus-infected CV-1 cells before addition to the wells to eliminate the nonspecific antibody. Biotin-labeled anti-mouse IgG (Vector, CA, USA) or IgA (CALTAG, CA, USA) was used as the detection antibody. Following 1 h incubation, the plates were washed and further incubated with avidin-HRP (Vector, CA, USA). The reaction was developed using an ABTS substrate (Roch Diagnostic, Mannheim, Germany).
Generation of CTL effector cells
Effector cells were derived from spleen, MLN and PP cells as precursor CTLs. Aliquots of 5 Â 10 6 spleen cells were co-cultured with 2.5 Â 10 6 mitomycin C-treated autologous spleen cells labeled with a peptide at 371C in a CO 2 incubator. The effector cells generated were harvested after 5 days of culture.
Cytotoxicity assay
Target cells, A20.2J cells (2 Â 10 6 ), were incubated at 371C in a 5% CO 2 atmosphere with 10 mg/ml of P18 or control peptide for 16 h. The target cells were then washed and labeled with 51 Cr. The 51 Cr-labeled target cells were incubated for 5 h with effector cells. Spontaneous release varied from 5 to 10%. Percent lysis was calculated as ((experimental releaseÀspontaneous release)/(100% releaseÀspontaneous release)) Â 100. All the experiments were performed at least four times, and each experimental group consisted of five mice. , Tokyo, Japan) (1 mg/ml), and effector cells were then added. In a separate experiment, effector cells (10 7 cells) were preincubated with anti-CD4 mAb (GK1.5) or anti-CD8 mAb (Lyt2.2) (10 mg/ml) at 41C for 1 h, and then the labeled target cells were added. Blocking of cytolytic activities by these mAbs was assessed by a 5-h 51 Cr release assay.
Blocking of cytolysis
Statistical analysis
Statistical analysis was performed using Mann-Whitney's U test and Kruskal-Wallis test. Values are expressed as means7s.d.s. A 95% confidence limit was taken as significant (Po0.05).
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